Liquid biopsies come of age: towards implementation of circulating tumour DNA
By Jonathan C M Wan, C. Massie, J. García-Corbacho, F. Moulière, James D. Brenton, Carlos Caldas, S. Pacey, R. Baird, N. Rosenfeld. Nature Reviews. Cancer, 2017
2,429 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/9a811077f8e2b6c874faa182e899440e11f4665c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Pathology and Forensic Medicine
Citations in the corpus
- Genetics and biology of prostate cancer (2018, background): “The second strategy takes advantage of liquid biopsy technology to identify biomarkers involving CTCs, cell-free tumor DNA, microRNAs, and microvesicles isolated from the blood, urine, saliva, pleural effusions, and cerebrospinal fluid (Alix-Panabieres et al. 2012; Alix-Panabieres and Pantel 2014; H”
- Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, neutral): “One example is the presence of tumour DNA mismatch repair (MMR) The mechanisms of action or targets of the immunotherapy combinations currently being tested in the ongoing trials listed in TABLE 1 are represented schematically.”
- Tumor microenvironment complexity and therapeutic implications at a glance (2020, background): “From another perspective, cfDNA can also indicate genetic and epigenetic characterization of tumors cells with minimally non-invasive means, simply from the blood plasma and serum of the patients [207, 208] .”
- Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations (2018, background): “An intense area of research is the use of liquid biopsies to non-invasively genotype cell-free DNA (cfDNA) shed by tumours into plasma, which allows genetic sampling of more than one region of a cancer in a way that can be readily repeated as a tumour evolves 104,131–133 .”
- Current and Future Development in Lung Cancer Diagnosis (2021, background): “The first discovery of circulating DNA and RNA in the plasma of healthy and sick individuals commenced in 1948 [55].”
- Enhanced detection of circulating tumor DNA by fragment size analysis (2018, positive): “Current strategies to improve ctDNA detection rely on increasing depth of sequencing coupled with various error correction methods (2, 13, 14).”